Document Detail


Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C.
MedLine Citation:
PMID:  20070395     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Therefore we needed to establish a new regimen without ribavirin.
METHODS: We devised a new regimen (same-day beta/alpha2b) to administer IFN-beta and alpha2b on the same-day, and compared it with IFN-alpha2b alone and IFN-alpha2b plus ribavirin. The cases were 36 patients (26.1%) in whom ribavirin could not be used (young women, anemia, etc.) among 138 patients who underwent IFN treatment after ribavirin release.
RESULTS: The percentages of patients withdrawing due to side-effects were 6.8%, 18.8% and 17.0% in the treatment with same-day beta/alpha2b, IFN-alpha2b alone and IFN-alpha2b plus ribavirin groups, respectively. In genotype 1b, the sustained viral response (SVR) was 28.6% (4/14), 13.6% (3/22) and 25.0% (8/32) with a high viral load, and 91.7% (11/12), 27.3% (3/11) and 57.1% (4/7) with a low viral load for the respective groups. According to a study on viral half-life during the early phase of IFN therapy, there was no difference among the regimens of same-day IFN-beta/alpha2b, beta alone, alpha2b alone and twice-daily treatment with IFN-beta. Same-day beta/alpha2b treatment showed a significantly higher SVR rate in moving type patients with a genotype 1b/high viral load.
CONCLUSIONS: Same-day beta/alpha2b treatment resulted in few cases where therapy was discontinued and showed a high SVR rate. This regimen is especially appropriate in cases where ribavirin has been deemed unsuitable.
Authors:
Eiichi Tomita; Kazuki Ando; Jun-Ichi Sugihara; Youichi Nishigaki; Tetsuya Yamada; Ryoko Ando; Masao Takemura; Mitsuru Seishima
Related Documents :
1355475 - Psychophysiologic response during script-driven imagery as an outcome measure in posttr...
19541575 - Switch from a zdv/3tc-based regimen to a completely once daily (qd) regimen of emtricit...
19669285 - Sustained response to peginterferon alfa-2a (40 kd) with or without lamivudine in asian...
20662655 - Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pil...
15151525 - Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
326595 - An open comparative trial of vanquin tablets and pripsen granules in the treatment of t...
Publication Detail:
Type:  Journal Article     Date:  2010-01-11
Journal Detail:
Title:  Hepatology research : the official journal of the Japan Society of Hepatology     Volume:  40     ISSN:  1386-6346     ISO Abbreviation:  Hepatol. Res.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-16     Completed Date:  2011-07-14     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  9711801     Medline TA:  Hepatol Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  261-8     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Over-expression of Toll-like receptors and their ligands in small-for-size graft.
Next Document:  Serum HGF and TGF-beta1 levels after right portal vein embolization.